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Lipopolysaccharide Lowers Cholesteryl Ester Transfer Protein by
Activating F4/80+Clec4f+Vsig4+Ly6C Kupffer Cell Subsets
Sam J. L. van der Tuin, PhD;* Zhuang Li, MSc;* Jimmy F. P. Berbee, PhD; Inge Verkouter, MSc; Linda E. Ringnalda, MSc; Annette E. Neele,
MSc; Jan B. van Klinken, PhD; Sander S. Rensen, PhD; Jingyuan Fu, PhD; Menno P. J. de Winther, PhD; Albert K. Groen, PhD; Patrick C. N.
Rensen, PhD; Ko Willems van Dijk, PhD; Yanan Wang, PhD
Background-—Lipopolysaccharide (LPS) decreases hepatic CETP (cholesteryl ester transfer protein) expression albeit that the
underlying mechanism is disputed. We recently showed that plasma CETP is mainly derived from Kupffer cells (KCs). In this study,
we investigated the role of KC subsets in the mechanism by which LPS reduces CETP expression.
Methods and Results-—In CETP-transgenic mice, LPS markedly decreased hepatic CETP expression and plasma CETP
concentration without affecting hepatic macrophage number. This was paralleled by decreased expression of the resting KC
markers C-type lectin domain family 4, member f (Clec4f) and V-set and immunoglobulin domain containing 4 (Vsig4), while
expression of the inﬁltrating monocyte marker lymphocyte antigen 6 complex locus C (Ly6C) was increased. Simultaneously, the
ratio of plasma high-density lipoprotein-cholesterol over non–high-density lipoprotein-cholesterol transiently increased. After
ablation hepatic macrophages via injection with liposomal clodronate, the reappearance of hepatic gene and protein expression of
CETP coincided with Clec4f and Vsig4, but not Ly6C. Double-immunoﬂuorescence staining showed that CETP co-localized with
Clec4f+ KCs and not Ly6C+ monocytes. In humans, microarray gene-expression analysis of liver biopsies revealed that hepatic
expression and plasma level of CETP both correlated with hepatic VSIG4 expression. LPS administration decreased the plasma
CETP concentration in humans. In vitro experiments showed that LPS reduced liver X receptor-mediated CETP expression.
Conclusions-—Hepatic expression of CETP is exclusively conﬁned to the resting KC subset (ie, F4/80+Clec4f+Vsig4+Ly6C). LPS
activated resting KCs, leading to reduction of Clec4f and Vsig4 expression and reduction of hepatic CETP expression, consequently
decreasing plasma CETP and raising high-density lipoprotein (HDL)-cholesterol. This sequence of events is consistent with the anti-
inﬂammatory role of HDL in the response to LPS and may be relevant as a defense mechanism against bacterial infections. ( J Am
Heart Assoc. 2018;7:e008105. DOI: 10.1161/JAHA.117.008105.)
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K upffer cells (KCs) are the resident tissue macrophages ofthe liver. KCs are characterized by speciﬁc surface
proteins such as Clec4f (C-type lectin domain family 4,
member f) and Vsig4 (V-set and immunoglobulin domain
containing 4).1–4 These surface markers distinguish KCs from
other hepatic macrophages, which may have lost or have yet
to acquire these KC markers. KCs play an important role in
the response to various harmful agents such as intestine-
derived bacterial lipopolysaccharide (LPS) in the portal blood.
LPS, a constituent of Gram-negative bacteria, is a potent
endotoxin that induces a strong cytokine-mediated inﬂamma-
tory response in the host.5 LPS activates KCs via the Toll-like
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receptor 4 (TLR4) signaling pathway to release proinﬂamma-
tory cytokines, such as tumor necrosis factor a (TNFa)6 and
interleukin-1b (IL-1b).7 Therefore, KCs are crucial to detect
LPS and trigger an antibacterial response.8,9
We have recently shown that KCs are the main source of
plasma cholesteryl ester transfer protein (CETP), and that
plasma CETP concentration predicts hepatic macrophage
content in humans.10 In that study, we also found that CETP
was expressed by only a subset of hepatic macrophages in
livers of both humans and mice transgenic for human CETP.
Plasma CETP plays a pivotal role in the metabolism of high-
density lipoproteins (HDL) and (very-) low-density lipoproteins
((V)LDL) by mediating the exchange of cholesteryl ester for
triglycerides (TG) between HDL and (V)LDL. Genetic deﬁciency
for CETP increases plasma HDL-cholesterol (C) and decreases
cardiovascular events.11 This has led to the development of
CETP inhibition as a potential strategy for the treatment of
cardiovascular disease. Despite clearly favorable effects on
the lipoprotein proﬁle, pharmacological CETP inhibitors, such
as torcetrapib,12 dalcetrapib13 and evacetrapib,14 failed to
show clinical beneﬁt on cardiovascular disease outcomes
including atherosclerosis and vascular inﬂammation. While,
recently, the Merck Company announced that the REVEAL
(Evaluation of the Effects of Anacetrapib through Lipid
Modiﬁcation) study, which studies the effects of Anacetrapib
on cardiovascular disease outcome met its primary end point,
signiﬁcantly reducing major coronary events deﬁned as the
composite of coronary death, myocardial infarction, and
coronary revascularization.15 These results illustrate that the
role and underlying mechanism of CETP in cardiovascular
disease pathology is more complex than initially anticipated.
CETP not only has a role in lipid and lipoprotein
metabolism, but also belongs to the family of lipid transfer/
LPS-binding proteins (LT/LBP).16 A previous study has
demonstrated that CETP expression increases the mouse
survival rate after injection of a lethal dose of LPS.17 In
addition, LPS administration to CETP transgenic mice resulted
in a rapid and marked decrease in plasma CETP concentration
and hepatic CETP expression, accompanied by an increase in
HDL-C level.18 These data indicate that CETP may play a
complex role in the response to LPS.
We previously observed that a subset of F4/80-positive
hepatic macrophages co-express CETP.10 In the current study,
we determined which subset of KCs is the predominant cellular
source to the plasmaCETP pool. Also, we investigated the role of
KC subsets in the mechanism by which LPS reduces CETP
expression. To this end, we determined the regulation of CETP in
relation to hepatic macrophagemarkers after injection of LPS in
APOE*3-Leiden.CETP (E3L.CETP)mice and followed the kinetics
of reappearance of CETP in relation to macrophage markers
after removal of hepatic macrophages by liposomal clodronate.
Furthermore, liver biopsies and plasma samples from 2 clinical
studies were used to evaluate the CETP expression in KC
subsets and effects of LPS on plasma CETP in humans.
Methods
The data, analytic methods, and study materials will not be
made available to other researchers for purposes of repro-
ducing the results or replicating the procedure.
Animals and Experimental Procedure
Female APOE*3-Leiden.CETP (E3L.CETP) transgenic mice19
were housed under standard conditions with a 12-hour light-
dark cycle and had free access to food and water during the
experiment. At the age of 10 to 15 weeks,mice were fed a semi-
synthetic cholesterol-rich diet, containing 15% (w/w) cacao
butter, 1% (w/w) corn oil and 0.1% cholesterol (w/w, Western-
type diet; AB-Diets, Woerden, The Netherlands) for a run-in
period of 6 weeks, followed by LPS injection or liposomal
clodronate injection. Body weight and food intake were mon-
itored during this study. The Institutional Ethics Committee for
Animal Procedures from the Leiden University Medical Centre,
Leiden, The Netherlands, approved the following studies.
LPS Injection
After randomization according to plasma levels of triglyc-
erides, total cholesterol, HDL-C, body weight, and age, mice
Clinical Perspective
What Is New?
• Our ﬁndings show that hepatic CETP (cholesteryl ester
transfer protein) is exclusively expressed by a resting
Kupffer cell subset (ie, F4/80+Ly6CClec4f+) but not by
activated macrophages or monocytes in the liver.
• Lipopolysaccharide exposure reduces hepatic CETP expres-
sion by activation of resting Kupffer cells, consequently
decreasing plasma CETP and raising high-density lipopro-
tein-cholesterol.
What Are the Clinical Implications?
• This rapid conversion of the Kupffer cell subset by LPS,
consequent loss of CETP expression and subsequent
increase in plasma high-density lipoproteins may play a
role in the host defense against Gram-negative bacterial
infections.
• The strong association between the expression of CETP and
activation markers by Kupffer cells implies that modulating
high-density lipoprotein metabolism via CETP inhibition may
affect the inﬂammatory status of the liver.
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received an intraperitoneal injection of LPS (25-lg per mouse;
Escherichia coli serotype 055:B5, Sigma-Aldrich) or vehicle
(LPS-free phosphate-buffered saline, control group), and blood
samples were drawn before and 8, 24, and 48 hours after the
injection. In a second study, mice were terminated 4, 8, and
48 hours after the injection of LPS.
Liposomal Clodronate Injection
After randomization according to plasma total cholesterol (TC),
HDL-C, triglycerides, body weight and age, ensuring that all mice
were equally old when they were euthanized, mice received 2
intraperitoneal injections of liposomal clodronate (20 mg/kg
bodyweight; purchased fromDr N. van Rooijen, Amsterdam) at a
3-day interval to deplete macrophages from the liver.10 Blood
samples were drawn before and after the second injection
weekly up to 9 weeks. In a second study, mice were terminated
3 days (0 week), or 3, 6, or 9 weeks after the second injection.
Control mice received no liposomal clodronate treatment.
Blood Sampling, Plasma Lipid, and Lipoprotein
Proﬁles
Blood was obtained via tail vein bleeding into heparin-coated
capillary tubes. The tubes were placed on ice and centrifuged,
and obtained plasma was snap-frozen in liquid nitrogen and
stored at 80°C until further measurements. Plasma was
assayed for triglycerides and cholesterol using the commer-
cially available enzymatic kits 11488872 and 236691 (Roche
Molecular Biochemicals, Indianapolis, IN, USA), respectively. To
measure plasma HDL-C, apoB-containing lipoproteins were
precipitated from plasma with 20% polyethylene glycol 6000
(Sigma Aldrich) in 200 mmol/L glycine buffer (pH 10) and HDL-
C was measured in the supernatant. Plasma non–HDL-C was
calculated by subtracting HDL-C from plasma total cholesterol.
Plasma CETP Concentration
Plasma CETP concentration was measured using the DAIICHI
CETP ELISA kit according to manufacturer’s instructions
(Daiichi, Tokyo, Japan).
Hepatic Gene Expression
Liver pieces were isolated and total RNA was extracted using
the Nucleospin RNAII kit (Macherey-Nagel) according to
manufacturer’s protocol. RNA concentration was determined
by Nanodrop technology (Thermo Scientiﬁc). Total RNA was
reverse-transcribed with the iScript cDNA synthesis kit (Bio-
Rad) and qPCR was performed using a CFX96 (Bio-Rad). Gene
expression was normalized to Beta-2 microglobulin (b2m),
hypoxanthine ribosyltransferase (Hprt) and Beta-actin (bactin).
Relative expression was calculated and normalized to control
group using Bio-Rad CFX ManagerTM software 3.0 (Bio-Rad).
Primer sequences can be found in Table S1.
Liver Histology
Parafﬁn-embedded sections of mouse liver (5 lm) were
stained for F4/80 and human CETP (ab51771; 1/1000,
Abcam) as described previously,10 Clec4f (MAB2784; 1/
1000, R&D Systems), Vsig4 (AF4674; 1/1000, R&D Systems)
and Ly6C (ab15627; 1/400, Abcam). For immunoﬂuores-
cence staining, the secondary antibodies donkey anti-rabbit
Alexa488 (A21206; Invitrogen) and goat anti-rat Alexa555
(A21434; Invitrogen) were used. Finally, tissue sections were
mounted with VECTASHIELD Mounting Medium with DAPI
(Vector Laboratories). Positive cells were counted using a
LeicaCTR5500 ﬂuorescence microscope (Leica Microsystems
GmbH). Representative pictures of immunostaining for CETP
in liver sections of non-CETP transgenic mice (APOE*3-Leiden
mice), APOE*3-Leiden.CETP transgenic mice, and a healthy
human donor are shown in Figure S1.
Design of Human Studies
Ninety-three severely obese subjects (BMI 30–74) underwent
elective bariatric surgery from 2006 to 2009 at the Depart-
ment of General Surgery, Maastricht University Medical
Center, Maastricht, The Netherlands, as described.20 Subjects
using anti-inﬂammatory drugs or having acute or chronic
inﬂammatory diseases, degenerative diseases, and subjects
reporting alcoholic intake >10 g/day, were excluded. During
surgery, liver biopsies were taken for mRNA isolation and
in situ analyses. Venous blood samples were obtained after
overnight fasting (8 hours) on the morning of surgery for
analysis of the plasma CETP concentration. This study was
approved by the Medical Ethics Board of Maastricht University
Medical Centre, in line with the Declaration of Helsinki. All
participants provided informed written consent.
The second study consisted of 20 healthy male subjects as
described.21 Subjects with known genetic causes for low HDL-
cholesterol, secondary dyslipidemias such as familial combined
hyperlipidemia, metabolic syndrome or secondary to hyper-
triglyceridemia, were excluded. On the morning of the study day
at 7:30 AM after an overnight fast, study participants were
admitted to the researchunit. At 7:45 AMa catheterwas inserted
in an antecubital vein of each arm. At 8:00 AM (time [t]=0), blood
was drawn for baseline measurements. Subsequently, subjects
received a bolus infusion of 1 ng/kg body weight of endotoxin
(E coli LPS, catalog number 1235503, lot G2B274; United
States Pharmacopeial Convention Inc, Rockville, MD) in the
antecubital vein of the contralateral arm. The next morning at
8:00 AM, 24 hours after endotoxin infusion, study participants
DOI: 10.1161/JAHA.117.008105 Journal of the American Heart Association 3






















returned after an overnight fast for the blood withdrawal. The
study protocol was approved by the institutional review board at
the Academic Medical Center in Amsterdam. Written informed
consent was obtained from all subjects.
In Vitro LPS Simulation in Human Monocyte-
Derived Macrophages
Peripheral blood mononuclear cells were isolated from a
buffycoat (Sanquin blood supply, Amsterdam, the Nether-
lands) through density centrifugation using LymphoprepTM
(Axis-Shield, Dundee, Scotland). Monocytes were then puriﬁed
using human CD14 magnetic beads and MACS cell separa-
tion columns (Miltenyi Biotec, Bergisch Gladbach, Germany).
Monocytes were plated in 24-well tissue culture plates at a
density of 19106 cells/mL (500 lL per well) and differenti-
ated to macrophages for 6 days in Iscove’s Modiﬁed
Dulbecco’s Medium (Sigma-Aldrich) supplemented with
2 mmol/L L-glutamine, penicillin (100 U/mL), streptomycin
(100 lg/mL) and 10% fetal calf serum (All Gibco, Waltham,
MA) in the presence of 50 ng/mL macrophage colony
stimulating factor (MCSF) (Miltenyi Biotec, Bergisch Gladbach,
Germany). On day 3, the medium was removed and substi-
tuted by fresh Iscove’s Modiﬁed Dulbecco’s Medium with 10%
fetal calf serum and 50 ng/mL MCSF. On day 6, all medium
was removed and replaced by Iscove’s Modiﬁed Dulbecco’s
Medium with 10% fetal calf serum without MCSF and cells
were activated for 18 hours with vehicle (DMSO), LPS
(10 ng/mL, Sigma-Aldrich), a liver X receptor (LXR) agonist
(TO-901317, 10 lmol/L, Sigma-Aldrich), and LPS+LXR ago-
nist. Total RNA was extracted from the cell lysate.
Statistical Analysis
Data were analyzed by Graphpad Prism software, version 7,
unless indicated otherwise. Signiﬁcance of differences
between the groups was calculated non-parametrically using
a Mann–Whitney U test for independent samples. All groups
were compared with the control group. Bonferroni’s method
was used to determine signiﬁcance in case of multiple
comparisons. For the human LPS exposure study, the Student
paired t test was used. To analyze the in vitro LPS exposure
study, One-way ANOVA was used, followed by the Fisher’s
Least Signiﬁcant Difference (LSD) test to identify the differing
groups. Spearman correlation was used to determine the
correlations between parameters in both mouse and human
studies. Linear regression analysis was performed on the
associations between hepatic expression of CETP and macro-
phage markers and the coefﬁcients of determination (R2) were
reported. For linear regression analysis of human liver
microarray data, unadjusted Crude models (model 1) and a
Model adjusted for age and sex (model 2) were applied using
STATA Statistical Software, version 12.0. For experiments
involving repeatedmeasures of plasma lipids and CETP levels in
the same animal, we used a linear mixed-effects model with a
heterogeneous ﬁrst-order autoregressive covariance matrix
structure to model subject-speciﬁc deviances from the group
mean using IBM SPSS Statistical Software, version 23. Values
are presented asmeansSEM. P values <0.05were considered
statistically signiﬁcant for single comparison.
Results
LPS Reduces Hepatic CETP Expression, Paralleled
by Decreased Expression of Resting Kupffer Cell
Markers and Increased Expression of
Macrophage Activation Markers
To investigate the role of hepatic macrophages in the mech-
anism by which LPS reduces CETP expression, we determined
the regulation of CETP in relation to macrophage markers after
injection of LPS in E3L.CETP mice. As expected, LPS injection
caused a massive upregulation of hepatic mRNA expression of
Tnfa 21-fold, Il-1b 19-fold, and Mcp-1 (monocyte chemotactic
protein-1) 28-fold at 4 hours after injection (all P<0.001,
Figure 1A), indicating LPS-induced KC activation.6,7,22 LPS also
increased the expression of lipopolysaccharide-binding protein
(Lbp, Figure S2A). These effects were transient as gene
expression returned to baseline at 48 hours after injection.
LPS markedly decreased mRNA expression of Pltp (phospho-
lipid transfer protein) (Figure S2B) and ATP binding cassette
subfamily G member 1 (Abcg1) (Figure S2C) in liver, up to
48 hours after LPS injection. Simultaneously, LPS injection
rapidly and markedly decreased hepatic mRNA expression of
CETP (75% at 8 hours after injection; P<0.001, Figure 1B) in
E3L.CETP mice. At 48 hours after LPS injection, CETP expres-
sion was still reduced. In parallel, LPS markedly decreased the
hepatic expression of resting KC markers Clec4f and Vsig4 to a
similar extent (75% and 83% at 8 hours after injection;
P<0.01, Figure 1B). In contrast, LPS increased hepatic mRNA
expression of lymphocyte antigen 6 complex locus C (Ly6C), a
marker of inﬁltrating monocytes/macrophages23 (+48% at
8 hours after injection; P<0.001, Figure 1D). Correlation
analyses using data of all time points (Figure 1D) showed that
hepatic CETP expression strongly positively correlated with the
expression of Clec4f (r=0.735; P<0.001) and Vsig4 (r=0.904;
P<0.001), whereas hepatic expression of CETP inversely
correlated with Ly6C (r=0.493; P<0.05).
LPS Acutely Changes Kupffer Cell Subsets But
Not the Hepatic F4/80+ Cell Number
We next performed immunohistochemistry on liver sections
and the numbers of F4/80+, Ly6C+, Clec4f+and CETP+ cells
DOI: 10.1161/JAHA.117.008105 Journal of the American Heart Association 4






















were quantiﬁed. LPS administration did not affect the hepatic
total macrophage/monocyte content as evidenced by the
number of F4/80+ cells (Figure S3A). In line with the
observation that LPS markedly increased the gene expression
of Ly6C, LPS signiﬁcantly increased the number of Ly6C+
monocytes after 4 hours (2.6-fold) and 8 hours (3.4-fold)
(Figure S3B). LPS decreased the number of Clec4f+ KC only
after 48 hours (28%; P<0.01, Figure S3C), which coincided
with a tendency of a decreased number of CETP+ cells at
48 hours after injection (20%; P=0.06, Figure S3D). The
numbers of Clec4f+ cells and CETP+ cells were not affected at
4 and 8 hours after LPS injection, which may be explained by
a relatively slow turnover of CETP protein as compared with
mRNA. Collectively, these data indicate that LPS acutely
decreases hepatic CETP expression accompanied by changes
in KC subsets.
LPS Reduces Plasma CETP and Transiently
Increases Plasma HDL-C Level and
HDL-C/Non-HDL-C Ratio
Plasma CETP, lipid and lipoprotein concentrations were
assayed at baseline and 8, 24, 48 hours after LPS or vehicle
injection in E3L.CETP mice. LPS rapidly reduced plasma CETP
concentration already at 8 hours as compared with the control
group (51%; P<0.01, Figure 2A), and this reduction in plasma
CETP concentration persisted until 48 hours after injection,
consistent with the reduced hepaticCETPmRNA expression. As
compared with the control group, LPS signiﬁcantly decreased
plasma TG level after 24 and 48 hours (Figure 2B), and total
cholesterol level throughout the 48 hours (Figure 2C). To
investigate the effect of LPS on the distribution of cholesterol
over plasma lipoproteins, HDL-C and non–HDL-C levels were
Figure 1. LPS reduces hepatic CETP expression, paralleled by decreased expression of resting Kupffer cell markers and increased
expression of macrophage activation markers. Female APOE*3-Leiden.CETP mice fed a Western-type diet were intraperitoneally injected with
25 lg LPS, after which mice were euthanized at the indicated time points. Livers were assayed for mRNA of (A) Tnfa, Il-1b, Mcp-1; (B) CETP
and (C) Clec4f, Vsig4, Ly6C. The correlations between hepatic mRNA expression of CETP with Clec4f, Vsig4 and Ly6C were performed, and
the goodness of ﬁt R2 from linear regression analyses were shown (D). For (A through C) data are presented as meansSEM (0, 4,
and 48 hours group: n=7; 8 hours group: n=8); *P<0.05, **P<0.01, ***P<0.001 as compared with the 0-hour group. CETP indicates
cholesteryl ester transfer protein; Clec4f, C-type lectin domain family 4; Il-1b, interleukin-1b; LPS, lipopolysaccharide; Ly6C, lymphocyte
antigen 6 complex locus C; Mcp-1, monocyte chemotactic protein-1; Tnfa, tumor necrosis factor a; Vsig4, V-set and immunoglobulin domain
containing 4.
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determined. LPS transiently tended to increase HDL-C level
8 hours after injection (+81%; Figure 2D), while persistently
decreasing non–HDL-C level throughout the 48 hours (Fig-
ure 2E). As a result, the HDL-C/non–HDL-C ratio transiently
increased at 8 hours after LPS injection (Figure 2F), suggesting
that LPS induced a rapid and transient shift of cholesterol from
non–HDL lipoproteins to HDL.
Reappearance of Hepatic CETP Expression After
Elimination of Hepatic Macrophages Coincides
With Reappearance of Hepatic Clec4f and Vsig4
Expression
Since LPS administration has similar time-dependent effects
on CETP expression and expression of the KC markers Clec4f
and Vsig4, we reasoned that CETP, Clec4f and Vsig4 may be
co-expressed by a similar subset of macrophages. This would
imply that, following elimination of hepatic macrophages,
reappearance of hepatic CETP expression caused by mono-
cyte inﬁltration would coincide with reappearance of Clec4f
and Vsig4. Therefore, in a next experiment we eliminated
hepatic macrophages from E3L.CETP mice by clodronate
injection, without induction of inﬂammation,24,25 and followed
the reappearance of CETP and macrophage markers in the
liver.
In line with our previous study,10 liposomal clodronate
rapidly and markedly decreased plasma CETP concentration
compared with vehicle (75%; Figure 3A). The plasma CETP
concentration was only gradually restored to levels observed
in the control group at 8 weeks after injection. Similarly,
liposomal clodronate virtually depleted the liver from CETP
mRNA (92%), which slowly returned to baseline levels
(control group) only 9 weeks after the injection. In contrast,
liposomal clodronate induced an immediate decrease in F4/
80 mRNA (82%), which was restored already 3 weeks after
injection (Figure 3B). Notably, the immediate effect of
liposomal clodronate treatment on mRNA expression of
Clec4f and Vsig4 paralleled the CETP mRNA expression, while
liposomal clodronate had virtually no effect on Ly6C mRNA
(Figure 3B). Furthermore, data on protein expression of the
macrophage subset markers are in line with data on mRNA
expression (Figures 3C and 4).
Figure 2. LPS reduces plasma CETP, and transiently increases plasma HDL-cholesterol level and HDL-C/
non–HDL-C ratio. Female APOE*3-Leiden.CETP mice fed a Western-type diet were intraperitoneally injected
with 25 lg LPS or vehicle (control), after which blood samples were collected at the indicated time points.
Plasma was assayed for CETP concentration and data are expressed relative to t=0 (A). Plasma levels of
triglyceride (B), total cholesterol (C), HDL-cholesterol (HDL-C, D), non-HDL-C (E) were determined, and the
ratio between HDL-C and non–HDL-C (F) was calculated. Data are presented as meansSEM (control and
LPS group: n=7); *P<0.05, **P<0.01, ***P<0.001 as compared with the control group. CETP indicates
cholesteryl ester transfer protein; HDL-C, high-density lipoprotein-cholesterol; LPS, lipopolysaccharide.
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Correlation analyses between hepatic expression of CETP
and macrophage marker genes (Figure 5A through 5C), or the
number of CETP+ cells and Clec4f+ cells, Vsig4+ cells, as well
as Ly6C+ cells (Figure 5D and 5E), again showed strong
positive correlations between CETP and Clec4f (Figure 5A and
5D) or Vsig4 (Figure 5B and 5E), and less clear correlation
between CETP and Ly6C (Figure 5C and 5F).
CETP is Exclusively Expressed by Clec4f+ Kupffer
Cells
To assess whether the strong correlations observed between
hepatic CETP and Clec4f/Vsig4 (both mRNA expression and
number of positive cells) are because of co-expression, we
next performed double immunoﬂuorescence staining of CETP
and F4/80, Clec4f, or Ly6C on liver sections. Hepatic CETP
co-localized in cells that also express F4/80, albeit that only a
subset of F4/80+ cells (65.49.9%) were CETP positive
(Figure 6A), which is in agreement with our previous
ﬁndings.10 While Ly6C+ cells did not stain for CETP protein
(only 4.43.9% Ly6C+ cells were CETP positive, Figure 6B),
94.98.7% Clec4f+ cells stained positive for CETP protein
(Figure 6C).
In Humans, Plasma CETP Concentration
Correlates With Hepatic VSIG4 Expression and is
Reduced by LPS Injection
By using previously generated microarray gene expression
data from liver biopsies of 93 subjects who underwent
elective bariatric surgery,20 we evaluated the correlation
between hepatic expressions of CETP with markers for
macrophage subsets in humans. In line with ﬁndings from
E3L.CETP mice, hepatic expression of CETP in humans
correlated with VSIG4 (r=0.441; P<0.001, Figure 7A), but
not CD14 (Figure 7B), a marker for human monocytes.26
Figure 3. Reappearance of hepatic CETP expression after removal of hepatic macrophages coincides with reappearance of hepatic Clec4f and
Vsig4 but not Ly6C. Female APOE*3-Leiden.CETP mice fed a Western-type diet were intraperitoneally injected with liposomal clodronate (Lip
Clo) and euthanized 3 days (0), 3, 6, and 9 weeks after injection. Untreated mice were taken along as control. Blood samples were collected at
the indicated time points and plasma was assayed for plasma CETP (A). Livers were assayed for mRNA (B) and protein (C) of CETP, F4/80,
Clec4f, Vsig4 and Ly6C. Data are presented as meansSEM (control and 0-week group: n=9; 3, 6, and 9 weeks group: n=7). *P<0.05,
**P<0.01, ***P<0.001 compared with the control group. CETP indicates cholesteryl ester transfer protein; Clec4f, C-type lectin domain family
4; Lip Clo, liposomal clodronate; Ly6C, lymphocyte antigen 6 complex locus C; Vsig4, V-set and immunoglobulin domain containing 4.
DOI: 10.1161/JAHA.117.008105 Journal of the American Heart Association 7






















Importantly, hepatic VSIG4 expression signiﬁcantly correlated
with plasma CETP concentration in these subjects (r=0.303;
P<0.05, Figure 7C). Adjustment for age and sex did not
change these ﬁndings (not shown). Also, from a publicly
available large data set of subjects undergoing bariatric
surgery,27 we previously observed a high correlation between
hepatic expression of CETP and the general macrophage
marker MARCO (r=0.62, P=1.7491071).10 Using data from
the same database, we now observed an even better
correlation between the hepatic expression of CETP and
VSIG4 (r=0.67, P=5.2791086) (Figure S4), which suggests
that, in humans, CETP is also expressed by KCs.
To evaluate whether LPS lowers plasma CETP levels in
humans similarly as in E3L.CETP mice, we determined CETP
levels in 20 healthy males just before and 24 hours after
administration of LPS.21 Indeed, we observed that LPS also
decreases plasma CETP concentration in humans (10%;
P<0.001, Figure 7D).
LPS Stimulation Decreases the LXR-Mediated
Upregulation of CETP and VSIG4
In search for the underlying mechanism why KCs show
decreased CETP expression in response to LPS, we performed
an in vitro experiment using human peripheral blood mono-
cyte-derived macrophages. As expected, treatment with the
liver X receptor (LXR) agonist TO-901317 strongly increased
mRNA expression of the target genes ABCG1 (15-fold,
Figure 7E) and CETP (6-fold, Figure 7F). Interestingly, stimu-
lation with LPS decreased the LXR-mediated upregulation of
ABCG1 (Figure 7E) and CETP (Figure 7F), while LPS alone had
no effect. Notably, the LXR agonist also increased the
Figure 4. Reappearance of hepatic CETP protein and hepatic macrophage subsets after liposomal clodronate injection. Female APOE*3-
Leiden.CETP mice fed a Western-type diet were intraperitoneally injected with liposomal clodronate (Lip Clo) and euthanized 3 days (0), 3, 6,
and, 9 weeks after injection. Untreated mice were taken along as control (Con). Representative pictures of immunohistochemistry staining of
CETP, F4/80, Clec4f, Vsig4 and Ly6C in liver sections from each group are shown. CETP indicates cholesteryl ester transfer protein; Clec4f, C-
type lectin domain family 4; Lip Clo, liposomal clodronate; Ly6C, lymphocyte antigen 6 complex locus C; Vsig4, V-set and immunoglobulin
domain containing 4.
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expression of VSIG4 (+39%; P<0.05), which was similarly
counteracted by LPS stimulation (Figure 7G). Collectively,
these data suggest that LPS decreases the LXR-mediated
upregulation of CETP and VSIG4 in KCs.
Discussion
In the present study, we investigated the role of KC subsets in
the mechanism by which LPS reduces hepatic CETP expres-
sion and plasma CETP concentration. Our data showed that
LPS rapidly and markedly reduces hepatic expression of CETP
in parallel with KC activation and reduced expression of resting
KC markers, without affecting the hepatic macrophage
content. The reduction in hepatic CETP expression caused a
decrease in plasma CETP concentration, and consequently a
shift of plasma cholesterol from non-HDL lipoproteins to HDL.
We next conﬁrmed that hepatic CETP is exclusively conﬁned to
the resting KC subset (ie, F4/80+Ly6CClec4f+Vsig4+), while
being absent from immature monocytes and/or activated KCs
in the liver (ie, F4/80+Ly6C+Clec4fVsig4). Our data indi-
cated that LPS regulates CETP expression and plasma
lipoprotein composition via activating the resting KC subset.
We have previously demonstrated that the liver is the main
source of plasma CETP, and that hepatic macrophages are
responsible for the expression of CETP in humans and CETP
transgenic (E3L.CETP) mice.10 Furthermore, a recent study in
which hepatectomized mice were repopulated with human
primary hepatocytes showed that these liver-humanized mice
did not express CETP in the liver and completely lacked CETP
in serum,28 conﬁrming that human hepatocytes do not
express CETP. In addition, we observed that not all hepatic
macrophages produce CETP, as supported by the fact that in
the liver only 57% of F4/80+ macrophages co-express CETP in
E3L.CETP mice and 39% of CD68+ macrophages co-express
CETP in humans.10 In the current study, double immunoﬂu-
orescence staining of liver sections of E3L.CETP mice
demonstrated that the CETP protein is conﬁned to F4/
80+Ly6CClec4f+ hepatic macrophages, and absent from F4/
80+Ly6C+Clec4f macrophages. Additionally, the kinetics of
the restoration of plasma CETP concentration and hepatic
macrophage subsets upon liposomal clodronate injection
indicated that F4/80+Ly6CClec4f+ macrophages in the liver
are the predominant cellular source of the plasma CETP pool.
It should be noted that F4/80 is a general marker for
Figure 5. Hepatic CETP mRNA and positive cells strongly correlate with those of Clec4f and Vsig4, but not Ly6C. The correlations between
hepatic CETP mRNA (A through C) or protein (D through F) with Clec4f (A and D), Vsig4 (B and E) and Ly6c (C and F) were performed, and the
goodness of ﬁt R2 from linear regression analyses was shown. CETP indicates cholesteryl ester transfer protein; Clec4f, C-type lectin domain
family 4; Ly6C, lymphocyte antigen 6 complex locus C; Vsig4, V-set and immunoglobulin domain containing 4.
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monocytes and macrophages including, but not restricted to,
KCs.3,29 Clec4f, also known as Kupffer cell receptor, has been
identiﬁed as an exclusive marker for the resting KC.3,30 The
reappearance of the different macrophage subsets indicated
that Clec4f+ KCs take longer to reappear in the liver than F4/
80+ macrophages (9 weeks versus 3–6 weeks), conﬁrming
Figure 6. CETP protein is not co-localized with Ly6C protein, but does co-localize with Clec4f protein.
Livers of non-injected female APOE*3-Leiden-CETP mice were assayed for co-localization of CETP and
F4/80 (A), Ly6C (B) and Clec4f (C). Red; F4/80, Ly6C or Clec4f, Green; CETP, Blue; DAPI. Double headed
arrows indicate co-localization, single-headed arrows indicate no co-localization. CETP indicates
cholesteryl ester transfer protein; Clec4f, C-type lectin domain family 4; Ly6C, lymphocyte antigen 6
complex locus C.
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that F4/80+Clec4f+ KCs are more mature KCs than F4/
80+Clec4f macrophages. In contrast to mice, in humans
CLEC4F expression is not conﬁned to liver macrophages,
while VSIG4 is exclusively expressed by resting mature
KCs.2,31 Here, we showed in mice that Vsig4 mRNA and
protein expression paralleled the reappearance of Clec4f and
CETP expression. Gene expression analysis using microarrays
of 93 liver biopsies obtained from bariatric surgery revealed a
strong correlation between hepatic CETP expression and
VSIG4 expression in humans. Also, plasma CETP concentra-
tion correlates with VSIG4 expression in human livers.
Therefore, we conclude that hepatic CETP expression in
Figure 7. LPS reduces plasma CETP concentration that correlates with hepatic VSIG4 expression in
humans. Ninety-three liver biopsies were taken during bariatric surgery, and assayed for gene expression by
microarray analysis. The correlation between the expression of CETP and VSIG4 (A) and CD14 (B), and
plasma CETP concentration and VSIG4 expression (C) were determined, and the goodness of ﬁt R2 from
linear regression analyses was shown. D, Twenty healthy males received a bolus infusion of 1 ng/kg body
weight of LPS via the antecubital vein. After an overnight fast, blood samples were collected before
(baseline) and 24 hours after LPS infusion, and plasma CETP concentration was determined. ***P<0.001
as compared with the baseline. E through G, Human monocyte-derived macrophages were treated with
vehicle (control group), LPS (LPS group), TO-901317 (LXR group) and LPS+TO-901317 (LPS+LXR group).
The mRNA expression of ABCG1, CETP and VSIG4 was normalized to the Control group. Data are presented
as meansSEM (n=4). *P<0.05, **P<0.01, ***P<0.001. ABCG1 indicates ATP binding cassette subfamily
G member 1; CD14, cluster of differentiation 14; CETP, cholesteryl ester transfer protein; LPS,
lipopolysaccharide; VSIG4, V-set and immunoglobulin domain containing 4.
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humans is also conﬁned to resting KCs, which is thus the
predominant pool of plasma CETP.
We showed that a bolus injection of LPS into E3L.CETP
mice rapidly reduces hepatic CETP expression, without
affecting total hepatic macrophage content as shown by the
number of F4/80+ cells, indicating that LPS reduced CETP
expression in hepatic macrophages per se. This ﬁnding is in
concordance with previous in vitro data showing that LPS, and
other inﬂammatory stimuli, such as TNFa and interferon c
reduced CETP mRNA expression in bone marrow-derived
macrophages from CETP transgenic mice and in human
monocyte-derived macrophages.32 In fact, LPS strongly
reduced Clec4f expression in KCs in vitro.33 Also, we now
showed that upon LPS administration, hepatic CETP expres-
sion markedly positively correlates with the Clec4f expres-
sion, while it inversely correlates with the expression of Ly6C
and macrophage activation markers, ie, Tnfa, Il-1b and Mcp-1.
This acute-phase rise in Lbp expression is probably mediated
by proinﬂammatory cytokines, such as interleukin-1,34 which
has been shown to protect against LPS induced systemic
inﬂammation.35 We further observed that in healthy subjects,
LPS also rapidly decreases plasma CETP concentration. Given
the fact that hepatic CETP expression is conﬁned to F4/
80+Ly6CClec4f+Vsig4+ resting mature KCs, our data indicate
that LPS rapidly activates resting KCs to become Clec4f
macrophages in mice, or VSIG4 macrophages in human
livers, simultaneously reducing hepatic CETP expression and
decreasing plasma CETP concentration. The proinﬂammatory
signals derived from activated KCs, such as TNFa, IL-1b, and
MCP-1, may drive a vicious cycle activating F4/80+Ly6CV-
SIG4+ KCs to lose the expression of VSIG4. Indeed, a previous
study2 has demonstrated that VSIG4 expression is restricted
to resting macrophages and that expression was completely
lost in inﬂamed macrophages.
The CETP gene promoter contains LXR binding elements,36
and LXR activation strongly increases CETP gene expression
and plasma CETP levels.37 In addition, LXR signaling plays a
crucial role in driving the specialization of macrophage
subsets.38 In pursuit of the underlying mechanism why KCs
show decreased CETP expression in response to LPS, we
treated human blood monocyte-derived macrophages with an
LXR agonist, LPS or both. Our data are consistent with a
mechanism in which LPS reduces the LXR-induced expression
of CETP in macrophages. Interestingly, we observed that LXR
activation also increased the expression of VSIG4, which was
counteracted by LPS stimulation. Since the promoter of VSIG4
contains no classical LXR-responsive element,39 the exact
mechanism underlying this upregulation is currently unknown
but may involve a distal or non-classical LXR-responsive
element. Nevertheless, it is thus likely that downregulation of
CETP and VSIG4 by LPS in the macrophage are parallel
events. Notably, LPS administration to mice also largely
decreased the mRNA expression of the LXR-target gene
Abcg1 in liver. Since Abcg1 mRNA expression levels in KCs is
70-fold higher than in parenchymal hepatocytes,40 our in vivo
data conﬁrm that LPS stimulation decreases LXR activation in
KCs.
CETP is a member of the LPS binding protein (LBP) family,
which includes PLTP (phospholipid transfer protein), BPI
(bactericidal permeability increasing protein) and LBP itself.
While LPS decreased CETP expression, it increased Lbp
expression. Interestingly, the reduction in Pltp mRNA expres-
sion, which is in line with previous ﬁndings,41 coincided with
the reduction in CETP mRNA expression. CETP has a low
binding afﬁnity to LPS (Kd >25 mmol/L), as compared with
LBP (Kd=0.8 nmol/L) and BPI (Kd=0.5 nmol/L).42 Therefore,
CETP likely only plays a role in LPS binding in the acute phase
of LPS exposure, when circulating LPS concentration is high.
This may explain the observation that CETP expression
markedly improves the mouse survival rate after injection of
a lethal dose of LPS.17 In addition, CETP plays an important
role in lipoprotein metabolism in humans. After secretion into
the circulation, the CETP protein binds mainly to HDL, and
promotes bidirectional transfer of CE, TG, and to lesser extent
phospholipid between plasma lipoproteins. Upon LPS admin-
istration, reduced plasma CETP concentration results in
increased HDL, which has well-documented anti-inﬂammatory
properties.43,44 A recent study showed that increasing HDL
via CETP inhibition inhibited neointimal hyperplasia in balloon-
injured rabbits, that the beneﬁt was attributed to the anti-
inﬂammatory properties of HDL.45 In fact, it has previously
been demonstrated that low HDL-C in healthy subjects was
associated with an increased inﬂammatory response to an
LPS challenge,21 further supporting the anti-inﬂammatory role
of endogenous HDL. It is thus tempting to speculate that
CETP-expressing species have increased ﬂexibility to respond
to invading Gram-negative organisms that release endotoxin/
LPS. The rapid conversion of KC subsets to lose CETP
expression and subsequently increase HDL may be of
importance in the defense against Gram-negative bacterial
infections.
It should be mentioned that the E3L.CETP mice express the
human CETP mini-gene under the control of its natural
ﬂanking regions.36 Although it cannot be excluded that some
regulatory elements may be missing from this construct, this
human CETP transgenic mice were shown to respond in a
human-like fashion to LXR agonism37 and FXR agonism.46
Notably, in E3L.CETP mice, the markedly increased HDL-C/
non–HDL-C ratio was already normalized at 48 hours after
LPS injection, whereas plasma CETP level and hepatic CETP
mRNA expression were still lower at this time point.
Moreover, in healthy subjects, 24 hours after LPS injection,
they had decreased plasma TG21 and CETP concentration as
shown in the present study, while plasma HDL-C was not
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changed.21 Together, this indicates that LPS exposure not
only affects CETP expression but also other pathways involved
in lipoprotein metabolism.47
In conclusion, our ﬁndings show that hepatic CETP is
exclusively expressed by resting KCs (ie, F4/80+Ly6C-
Clec4f+) but not by activated macrophages or monocytes in
the liver. In response to inﬂammatory stimuli, ie, LPS
exposure, resting KCs become activated and lose CETP
expression. As a consequence, plasma CETP concentration is
also rapidly decreased and HDL-C is raised. This sequence of
events may play a role in the host defense via the anti-
inﬂammatory effects of HDL. The strong association between
the expression of CETP and activation markers by KCs implies
that modulating HDL metabolism via CETP inhibition may
affect the inﬂammatory status of the liver.
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Table S1. Primers sequences use for RT-Qpcr. 
Gene Forward primer Reverse primer 
ABCG1 CAGGAAGATTAGACACTGTGG GAAAGGGGAATGGAGAGAAGA  
Abcg1 AGGTCTCAGCCTTCTAAAGTTCCTC TCTCTCGAAGTGAATGAAATTTATCG 
βactin AACCGTGAAAAGATGACCCAGAT CACAGCCTGGATGGCTACGTA 
β-2m TGACCGGCTTGTATGCTATC CAGTGTGAGCCAGGATATAG 
CETP CATGTCTCGGCTCGAGGTAG TTCTGCTACAAGCCCCATCC 
Clec4f ACTGAAGTACCAAATGGACAATGTTAGT GTCAGCATTCACATCCTCCAGA 
F4/80 CTTTGGCTATGGGCTTCCAGTC GCAAGGAGGACAGAGTTTATCGTG 
Hprt TTGCTCGAGATGTCATGAAGGA AGCAGGTCAGCAAAGAACTTATAG 
Il-1β GCAACTGTTCCTGAACTCAACT ATCTTTTGGGGTCCGTCAACT 
Lbp CCTGAGACTCGCCATCTCTGA AGGAGGAGGTCCACTGAAATG 
Ly6c CTGCAACCTTGTCTGAGAGGA GTCCCTGAGCTCTTTCTGCAC 
Mcp-1 GCATCTGCCCTAAGGTCTTCA TTCACTGTCACACTGGTCACTCCTA 
Pltp TCAGTCTGCGCTGGAGTCTCT AAGGCATCACTCCGATTTGC 
Tnfα AGCCCACGTCGTAGCAAACCAC TCGGGGCAGCCTTGTCCCTT 
Vsig4 TCACCTATGGCCACCCCACC AGGCGGCCTCTGTACTTTGCCT 
VSIG4 CACTGACATGGATGGCTACCT AAGACAGGCAGGCTCTTTCC 
 
  







Figure S1. CETP staining in mouse and human livers. 
 
 
Representative picures of IHC staining of CETP protein in liver sections of (A) non-CETP 
transgenic mice (APOE*3-Leiden mice), (B) APOE*3-Leiden.CETP transgenic mice, and (C) 
a healthy human donor.  
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Female APOE*3-Leiden.CETP mice fed a Western-type diet were intraperitoneally injected 
with 25 µg LPS, after which mice were sacrificed at the indicated time points. Livers were 
assayed for mRNA of (A) Lbp, (B) Pltp and (C) Abcg1. Data are presented as means ± SEM 
(n=7-8); **P<0.01, ***P<0.001 as compared to the 0 h group. 
  












Female APOE*3-Leiden.CETP mice fed a Western-type diet were intraperitoneally injected 
with 25 µg LPS, after which mice were sacrificed at the indicated time points. Livers were 
assayed for F4/80-positive macrophages (A), Ly6C-positive monocytes (B), Clec4f-positive 
Kupffer cells (C) and CETP-positive cells (D). Data are presented as means ± SEM (n=7-8); 
**P<0.01, ***P<0.001 as compared to the 0 h group. 
  











Scatter plots of the correlation between the expression of CETP and VSIG4 in liver was 
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